

## Zealand to present at 34<sup>th</sup> Annual J.P. Morgan Healthcare Conference on 14 January 2016

---

Copenhagen, 18 December 2015 – Zealand today announces that the company's CEO Britt Meelby Jensen will present at the 34<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Thursday, 14 January 2016 at the Westin St. Francis Hotel in San Francisco, California. The presentation will take place at 10:30 am PT (7.30 pm CET).

The presentation will focus on the acceleration of Zealand's strategic direction towards value generation - from peptide to patient - and will outline the company's pipeline and news flow outlook for 2016.

An audio webcast of the presentation will be available on the Investor Relations section of the company's website at [www.zealandpharma.com](http://www.zealandpharma.com).



### For further information, please contact:

**Hanne Leth Hillman**, Senior Vice President for Investor Relations and Communications  
Tel: +45 50 60 36 89, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)

### About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia<sup>®</sup> by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus<sup>®</sup>) which is on track for regulatory submission in the US in Q4 2015 and in the European Union in Q1 2016.

The proprietary pipeline includes; *danegaptide* for ischemic reperfusion Injuries in Phase II development; *ZP1848* for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, *ZP4207*, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as *several preclinical peptide therapeutics*.

The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: [www.zealandpharma.com](http://www.zealandpharma.com) or follow us on Twitter @ZealandPharma